We are the Artful Dodgers of the globalised world, experts at ducking and diving - but even the Dodger gets caught in the end ...
4dOpinion
What is happening today in Washington is a travesty. And the only ones who can prevent it from going further are the people ...
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...
Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...
The reason behind the shape of manhole covers have been revealed.
Zacks Investment Research on MSN2d
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for InvestorsIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%. At the ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
The Global 3D Cell Culture Market is expected to witness a double-digit growth rate by 2027. Some of the key factors driving ...
Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback